Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
111 hedge funds and large institutions have $354M invested in Five Prime Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
18% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 34
4% more funds holding
Funds holding: 107 → 111 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
30% less capital invested
Capital invested by funds: $504M → $354M (-$150M)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $634K
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.2M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$7.33M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$5.98M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.98M |
| 5 |
AAM
Aureus Asset Management
Boston,
Massachusetts
|
-$4.46M |
FPRX Hedge Fund Activity: Q3 2015 in Review
111 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2015, worth a combined $354M — down 30% from $504M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FPRX positions and 16 closed out — a net gain of 4 holders — while 40 added to existing stakes and 34 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $15.1M. The largest seller was Point72 Asset Management, cutting an estimated $10.2M.
- 111 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2015, up from 107 in Q2 2015.
- Funds reported $354M of Five Prime Therapeutics, Inc. stock for Q3 2015, down 30% quarter-over-quarter.
- 20 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2015 and 16 closed out, a net change of +4 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q3 2015 was Adage Capital Partners, an estimated $15.1M added.
- The largest Five Prime Therapeutics, Inc. seller in Q3 2015 was Point72 Asset Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2015.